NCT01738087View on ClinicalTrials.gov

Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Asthmatic

Interventions

DRUG

NEXThaler 100/6 mcg DPI

DRUG

Flixotide Accuhaler 500 mcg

Active comparator

DRUG

NEXThaler 200/6 mcg DPI

DRUG

NEXThaler placebo

Placebo comparator

Trial Locations (1)

M23 9QZ

The Medicine Evaluation Unit, Manchester

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT01738087 - Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder | Biotech Hunter | Biotech Hunter